Rubió invests €14 million to double production at its Castellbisbal factory.

BarcelonaThe Catalan pharmaceutical company Rubió has invested 14 million euros in the expansion of its production plant in Castellbisbal (Vallès Occidental). The expansion will double the current production capacity of approximately 10 million units to 20 million units, the company reported.

According to the company, the project will be completed in 2028 and will double the workforce: "Today we have approximately 100 people in the production area and with this project we expect to double the staff," stated Rubió's CEO, Pelayo Rubió. The laying of the foundation stone was held this Monday.

With this expansion, Rubió aims to strengthen its commitment to internationalization and to consolidate the pharmaceutical company "as a benchmark for quality and innovation in comprehensive healthcare," according to the executive. "Every year we invest to have a pipeline of ten new products and with this expansion we seek not only to cover the demand for current products, but also to satisfy the demand for these new developments of our own product," he added.

With a workforce of nearly 300 employees, Rubió has a commercial presence in more than 70 countries through 80 local partners and is actively working to grow. opened in 2001 and currently has a surface area of approximately 2,900 square meters.

International expansion

Formerly known as Laboratorios Rubió, the pharmaceutical company's main market is Europe, but it aims to expand into markets like the United States. "The business continues to grow nationally and internationally, and we believe in having our own factory so we don't have to outsource production," said Rubió's CEO.

In the therapeutic field, Rubió is a leader in the treatment of ADHD and maintains a consolidated position in rheumatology, nephrology, lupus, chronic kidney diseases, and central nervous system diseases.